AMRN Stock Analysis: Buy, Sell, or Hold?
AMRN - Amarin Corp Plc
$13.95
-0.50 (-3.46%)
▼
5d:
-4.45%
30d:
+1.09%
90d:
-1.34%
HOLD
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 06, 2026
Get Alerted When AMRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AMRN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: AMRN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$47.85
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$29.71
53.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 21.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AMRN is currently trading at $13.95, which is considered oversold relative to its 30-day fair value range of $14.11 to $15.56. From a valuation perspective, the stock is trading at a discount (Forward PE: 11.9) compared to its historical average (21.0). Remarkably, the market is currently pricing in an annual earnings decline of 17.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, AMRN is in a downtrend. The price is currently testing key support at $14.10. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: AMRN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. However, the stock is trading significantly above the average Wall Street target of $12.00. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AMRN is in a downtrend. The price is currently testing key support at $14.10. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: AMRN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. However, the stock is trading significantly above the average Wall Street target of $12.00. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$14.11 -
$15.56
Company Quality Score
49/100
(HOLD)
Options IV Signal
31th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
48.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 31th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BEARISH: Trading 14.0% above Wall St target ($12.00)
Fair Price Analysis
30-Day Fair Range
$14.11 -
$15.56
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$1.34
(9.6%)
Support & Resistance Levels
Support Level
$14.10
Resistance Level
$15.72
Current Trend
Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.92
Wall Street Target
$12.00
(-14.0%)
Revenue Growth (YoY)
-21.0%
Earnings Growth (YoY)
-94.2%
Profit Margin
-18.2%
Valuation Discount vs History
-17.2% cheaper
PE vs Historical
11.9 vs 21.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-17.2%
(market-implied from PE analysis)
1-Year Target
$12.55
(-10%)
2-Year Target
$11.30
(-19%)
3-Year Target
$10.17
(-27%)
3-Yr Target (if PE normalizes)
(PE: 12→21)
$17.91
(+28%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 50.0%)
$88.25
(+533%)
Base:
(SPY PE: 11.9, Growth: 50.0%)
$47.08
(+238%)
Bear:
(PE: 10.1, Growth: 50.0%)
$40.02
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.9 to 21.0
Stabilization Target:
$24.57
(+76.1%)
PE Expansion Potential:
+76.1%
Share & Embed Analysis
Last updated: March 31, 2026 3:33 AM ET
Data refreshes hourly during market hours. Next update: 4:33 AM
Data refreshes hourly during market hours. Next update: 4:33 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AMRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1209 | 54 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 56 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$206 | 64 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$351 | 58 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$249 | 56 HOLD |
